Determination PRALIDOXIME CHLORIDE (Autoinjector) (Pralidoxime Chloride) Solution, 600 Milligrams/2 Milliliters (300 Milligrams/Milliliter), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
By Health, Drug Administration, Human Services Department, Food · Oct 5, 2026, 11:00 PM CDT
The Food and Drug Administration (FDA, Agency, or we) has determined that PRALIDOXIME CHLORIDE (AUTOINJECTOR) (pralidoxime chloride) solution, 600 milligrams (mg)/2 milliliters (mL) (300 mg/mL), was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for pralidoxime chloride solution, 600 mg/2 mL (30
Excerpt shown under fair-use limits. Full text remains with the original publisher.
People in this coverage
Explore their history and attributable record. Being mentioned does not imply endorsement.
Layer 1 · Claims & fact checks
AI analysisLayer 3 · Reporting analysis
AI analysisFramingFrames the product positively by emphasizing the absence of safety or efficacy concerns.
Authority AppealUses the agency’s authority to lend credibility to the statement.
Future OrientationHighlights the procedural consequence of the determination, focusing on upcoming regulatory actions.
Context
AI analysisMissing context
The announcement does not explain the prior status of the product (e.g., whether it had ever been withdrawn, placed on hold, or subject to other regulatory actions) or the reasons why the FDA needed to issue this specific determination at this time.
Important context
The FDA’s determination is a regulatory clarification that the product’s market presence is not being limited due to safety or efficacy concerns, which is a prerequisite for approving future ANDAs for the same formulation.
Opinion vs. reporting
AI analysisThe text presents a factual regulatory announcement without editorial commentary or opinion.